Delivery Order SPE2DR25D9102-SPE2DR26FDDS0
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $10,586.94 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 10 mg tablets (30-count) with an ultimate completion date of January 5, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) with an ultimate completion date of December 2, 2025. This delivery order, issued on November 7, 2025, operates under a firm fixed-price contract structure with no set-aside designation, allowing the contract to compete in the unrestricted federal procurement marketplace. DMS Pharmaceutical Group Inc., a woman-owned small...
- The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count). This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,373.61 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nuplazid 10 mg tablets (30-count packages). The award, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries a firm fixed-price contract type with no set-aside designation, indicating the vendor competed in unrestricted federal...
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc. for 30 capsules of Nuplazid 34 mg on November 28, 2025. This firm fixed-price delivery order, issued without set-aside designation, will be performed in Park Ridge, Illinois, with an ultimate completion date of December 19, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Illinois, serves as the sole awardee and has been...
- The Defense Logistics Agency awarded a delivery order valued at $3,529.63 to DMS Pharmaceutical Group Inc. for 30-count bottles of Nuplazid 34 mg capsules, with a completion date of January 15, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order represents a firm fixed-price purchase issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $10,588.89 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units). The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count packages). The award, issued on October 28, 2025, with an ultimate completion date of November 19, 2025, utilizes firm fixed-price pricing and does not include a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on September 29, 2025, for the supply of Nuplazid (pimavanserin) 34 mg capsules in quantities of 30 units. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this delivery order under a firm fixed-price contract with a ceiling value of $10,375.53. The order represents no set-aside designation and carries an ultimate completion date...
- The Defense Logistics Agency awarded a $10,586.94 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for 30 tablets of Nuplazid 10 mg on December 12, 2025, with an ultimate completion date of January 6, 2026. This delivery order was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge,...
- SPE2DR25D9102Indefinite Delivery Contract
- SPE2DR25D9102-SPE2DR26FDDS0Delivery Order
The Defense Logistics Agency issued a delivery order valued at $3,925.34 to DMS Pharmaceutical Group Inc. for Nuplazid 10 mg tablets (30-count packaging) with an ultimate completion date of January 21, 2026. This firm fixed-price delivery order, awarded on December 29, 2025, was issued without a set-aside designation, reflecting the contractor's ability to compete in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the Department of Defense pharmaceutical supply chain and has demonstrated consistent performance across multiple product categories and therapeutic areas. This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, positioning the company as a regional prime vendor contractor within the $30.3 billion PPV-G GEN V acquisition strategy. This structure enables the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products—including branded and generic prescription medications, biologics, vaccines, and medical consumables—to support the recurring medical supply needs of military healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 12/28/25 |